(May 6, 2016) – PLx Pharma Inc. (PLx), a privately-held, late-stage specialty pharmaceutical company initially focused on developing its clinically validated PLxGuard™ delivery system to provide safer and more effective aspirin products, today announced the United States Patent and Trademark Office has provided an Issue Notification for two patents and a Notice of Allowance for a third additional patent that will issue following their administrative process. These patents cover PLx Pharma’s aspirin product in development, PL2200 Aspirin and other NSAID products utilizing the PLxGuard™ technology.
Notice of Allowance: r>
- Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity, application number 14495525, to expire in 2022.
Issued Patents: r>
- pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same, patent numbers 9226892 and 9216150, to expire in 2032. “We are excited to continue strengthening our intellectual property. These patents will enhance and expand intellectual property assets for PLx Pharma which include over 40 issued worldwide patents,” noted Natasha Giordano, President and Chief Executive Officer. r>
About PLx Pharma r>
PLx Pharma Inc. is a late-stage specialty pharmaceutical company initially focused on developing our clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products. Our PLxGuard™ delivery system works by releasing active pharmaceutical ingredients into the duodenum, the first part of the small intestine immediately below the stomach, rather than in the stomach itself. We believe this improves the absorption of many drugs currently on the market or in development, and reduces acute gastrointestinal (GI) side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs. To learn more about the Company and its pipeline, please visit www.plxpharma.com. Contact Information: Natasha Giordano ngiordano@plxpharma.com
Notice of Allowance: r>
- Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity, application number 14495525, to expire in 2022.
Issued Patents: r>
- pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same, patent numbers 9226892 and 9216150, to expire in 2032. “We are excited to continue strengthening our intellectual property. These patents will enhance and expand intellectual property assets for PLx Pharma which include over 40 issued worldwide patents,” noted Natasha Giordano, President and Chief Executive Officer. r>
About PLx Pharma r>
PLx Pharma Inc. is a late-stage specialty pharmaceutical company initially focused on developing our clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products. Our PLxGuard™ delivery system works by releasing active pharmaceutical ingredients into the duodenum, the first part of the small intestine immediately below the stomach, rather than in the stomach itself. We believe this improves the absorption of many drugs currently on the market or in development, and reduces acute gastrointestinal (GI) side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs. To learn more about the Company and its pipeline, please visit www.plxpharma.com. Contact Information: Natasha Giordano ngiordano@plxpharma.com
